Psych MEQs / SAQs · Intellectual disability psychiatry — genetic syndromes
Behavioural phenotypes and genetic syndromes (MEQ)
FRANZCP-style MEQ covering probabilistic behavioural phenotypes, 22q11.2DS/VCFS psychosis, comparative syndrome phenotypes, investigations and start-low go-slow antipsychotic principles.
On this page & tools
Target exams
Model answer
Reveal model answer
(i) Definition. A behavioural phenotype is the heightened probability that people with a given genetic syndrome will show particular cognitive, social, communicative and psychiatric patterns. Features are neither universal nor exclusive and do not replace a DSM/ICD psychiatric diagnosis.[1]
(ii) Likely diagnosis and risk. 22q11.2 deletion syndrome (VCFS/DiGeorge spectrum): conotruncal heart disease, palatal speech issues, hypocalcaemia history, ID and new psychosis. Adult schizophrenia-spectrum rates are very high in landmark VCFS work (Murphy) and consortium data support substantial psychosis risk into adulthood — longitudinal psychiatric care is mandatory.[2][3][4]
(iii) Comparative phenotypes. Down syndrome (trisomy 21): depression and early Alzheimer dementia risk with age; medical confounders common. Fragile X (FMR1 full mutation, typically greater than 200 CGG): ID, ASD features, ADHD, anxiety; X-linked; premutation relatives may have FXPOI/FXTAS clues. Prader-Willi (loss of paternal 15q11-q13 gene expression): hyperphagia, OCD-like behaviours, temper outbursts; psychosis especially with maternal UPD. Angelman (loss of maternal UBE3A): severe ID, minimal speech, seizures, happy demeanour, ataxia.[5][6][7][8][9]
(iv) Now. Medical: calcium/PTH, ECG, infection screen, substances, metabolic baseline before antipsychotic. Confirm/arrange 22q11.2 genetic documentation (often chromosomal microarray) and clinical genetics. Multisystem review (cardiac, immune, speech). Collateral MSE; risk assessment; capacity and least-restrictive legal status under local law. Early psychosis pathway with ID-adapted communication.[3][4]
(v) Psychopharmacology. Treat clear psychosis with an antipsychotic — start low, go slow in ID (e.g. risperidone oral 0.25–0.5 mg daily initially with slow titration, or alternative with attention to QTc/metabolic risk); monitor weight, glucose/lipids, EPS, prolactin as relevant; check calcium and cardiac status. Do not use antipsychotics as first-line for pure communication-driven behaviour without psychosis. Combine with psychosocial supports and carer education.[3][4]
Common errors
- Treating behavioural phenotype as pathognomonic.
- Missing 22q11 clues (heart, palate, calcium).
- Confusing PWS vs Angelman parental origin.
- Jumping to Alzheimer dementia in every DS behavioural change.
- Inventing foreign Mental Health Act section numbers. [1][2][5][6]
Examiner notes
High-scoring answers name Murphy, Schneider consortium, Boer UPD, and state probabilistic phenotype language. Mention cascade counselling only if time allows. [1][2][3][6]
References
- [1]Dykens EM Measuring behavioral phenotypes: provocations from the "new genetics" Am J Ment Retard, 1995.PMID 7779347
- [2]Murphy KC, Jones LA, Owen MJ High rates of schizophrenia in adults with velo-cardio-facial syndrome Arch Gen Psychiatry, 1999.PMID 10530637
- [3]Schneider M, Debbané M, Bassett AS, et al. Psychiatric disorders from childhood to adulthood in 22q11.2 deletion syndrome Am J Psychiatry, 2014.PMID 24577245
- [4]Bassett AS, McDonald-McGinn DM, Devriendt K, et al. Practical guidelines for managing patients with 22q11.2 deletion syndrome J Pediatr, 2011.PMID 21570089
- [5]Cassidy SB, Schwartz S, Miller JL, Driscoll DJ Prader-Willi syndrome Genet Med, 2012.PMID 22237428
- [6]Boer H, Holland A, Whittington J, et al. Psychotic illness in people with Prader Willi syndrome due to chromosome 15 maternal uniparental disomy Lancet, 2002.PMID 11809260
- [7]Hagerman RJ, Berry-Kravis E, Hazlett HC, et al. Fragile X syndrome Nat Rev Dis Primers, 2017.PMID 28960184
- [8]Antonarakis SE, Skotko BG, Rafii MS, et al. Down syndrome Nat Rev Dis Primers, 2020.PMID 32029743
- [9]Williams CA, Beaudet AL, Clayton-Smith J, et al. Angelman syndrome 2005: updated consensus for diagnostic criteria Am J Med Genet A, 2006.PMID 16470747